RSV usually only has mild symptoms, but it can lead to breathing problems in the most vulnerable infants. The vaccine is ...

Palivizumab was the only approved therapy to prevent severe RSV disease in infants and young children until the approval of nirsevimab in 2023.

Inpatient mortality and adverse outcomes were significantly more likely among adults hospitalized with RSV infection vs seasonal influenza.

In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency ...

RSV vaccine recommended for adults 60+ with health issues, infants under 19 months, and all healthy adults 75+. Helps prevent ...

The NHS has warned of a 'serious virus' after a surge in cases of respiratory syncytial virus (RSV) in Australia. Here's ...

RSV hospitalization was associated with increased risk for new CVEs and worsening of preexisting cardiovascular conditions.

Children under 2 years of age are at highest risk for getting critically ill from the flu or RSV and requiring intensive care. Currently, doctors can only provide breathing support for severe flu or ...

Australia saw a record number of RSV cases last year, and NHS officials have suggested that the Australian winter often ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

For newborns and infants, whose immune systems are still developing, and airways are small, RSV can quickly become serious.